Leonard Braden Michael's Form 4/A amendment
AmendedEnliven Therapeutics, Inc. (ELVN) · filed Jan 5, 2023
- Accession no.
- 0001567619-23-000570
- Filed
- Jan 5, 2023
- Trade date
- Jan 3, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Jan 4, 2023
This filing lists 1 non-derivative transaction. Open-market sales total $5.00M. It was filed 2 days after the trade.
This amendment replaces 0001567619-23-000371 (filed Jan 4, 2023).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Leonard Braden MichaelCIK 0001373603 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2023 | Common Stock | SSaleDisposed | −1,250,000 | $4.00 | −$5,000,000 | 1,767,774 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
- F2
This form was filed to correct the transaction date to 1/3/2023.